Trial · NCT03473964
(ACTH) for the Treatment of Sarcoid Uveitis
NCT03473964, Unknown, John Huang, MD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. (ACTH) for the Treatment of Sarcoid Uveitis. Trials, record NCT03473964. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03473964
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- (ACTH) for the Treatment of Sarcoid Uveitis
- NCT number
- NCT03473964
- Status
- Unknown
- Enrollment
- 10 participants, estimated
- Lead sponsor
- John Huang, MD
- Conditions
- Sarcoid Uveitis
- Interventions
- H.P. Acthar gel
- First posted
- 2018-03-22
- Last updated
- 2018-03-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Degree of aqueous and vitreous inflammatory cells-change is being assessed | 0 weeks, 4 weeks, 12 weeks and 24 weeks. | Degree of aqueous and vitreous inflammatory cells as graded by the criteria established by the Standardization of Uveitis Nomenclature (SUN) |
| Secondary | Degree of aqueous flare- change is being assessed | 0 weeks, 4 weeks 12 weeks and 24 weeks | Degree of aqueous flare as graded by the criteria established by Standardization of Uveitis Nomenclature (SUN) |
| Secondary | Visual acuity- change is being assessed | 0 weeks, 4 weeks, 12 weeks and 24 weeks | Testing and evaluation of best corrected visual acuity using Luxvision trial frames and Precision Vision ETDRS charts R,1 and 2 |
| Secondary | Central macular thickness- change is being assessed | 0 weeks, 4 weeks, 12 weeks and 24 weeks | Central macular thickness as measured by Spectralis Optical Coherence Tomography (OCT) |
| Secondary | Intraocular pressure | 0 weeks, 4 weeks, 12 weeks and 24 weeks | Intraocular pressure as measured by applanation tonometry |
| Secondary | Quality of life assessment- change is being assessed | 0 weeks, 4 weeks, 12 weeks and 24 weeks | Quality of life assessment using the National Eye Institute Visual Function Questionnaire (VFQ-25). The VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single item general health rating question. The scoring ranges in scores from 1-6, 1 being activity presents no difficulty and 6 being can no longer perform this activity due to vision. The VFQ-25 generates the following vision-targeted subscales : global vision rating (1), difficulty with near vision activities (3), difficulty with distance vision activities (3), limitations in social functioning due to vision (2), role limitations due to vision(2), dependency on others due to vision (3), mental health symptoms due to vision (4), driving difficulties (3), limitations with peripheral (1) and color vision (I), and ocular pain (2). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03473964
GET https://conductscience.org/api/trials/v1/NCT03473964/registered